This proposal aims to identify and validate novel circulating metabolic biomarkers to address critical, unmet needs in cardiovascular disease management. Our studies will specifically focus on myocardial ischemia and early injury, for which no suitable and clinically practical blood biomarkers presently exist. Our goal is to build on our initial observations and working hypotheses that an unbiased metabolomics discovery platform will yield novel biomarkers, and that simultaneous assessment of multiple biomarkers examining different pathophysiological axes will provide complementary information to improve diagnosis and clarify prognosis. Newly developed metabolomics techniques, richly-annotated clinical samples, as well as novel biomarkers already identified serve as the underpinnings for the proposed studies:
In Specific Aim 1, we will use our LC- MS/MS-based metabolomics platform to identify novel early markers of myocardial injury in three unique cohorts of patients experiencing planned myocardial ischemia or injury: patients undergoing cardiac exercise stress testing with myocardial perfusion imaging, patients subjected to pacing-induced myocardial ischemia in the cardiac catheterization suite, and patients experiencing a planned myocardial infarction for hypertrophic cardiomyopathy.
In Specific Aim 2, we will then characterize novel early markers of myocardial injury in carefully phenotyped cohorts of healthy controls, patients with stable coronary artery disease (CAD), and patients presenting across the spectrum of acute coronary syndromes (ACS).
In Aim 3 a, we will test the hypothesis that the novel biomarkers will aid diagnosis in two currently challenging clinical settings. First, we will test whether measurement of the biomarkers in patients undergoing exercise stress testing will enable the detection of inducible myocardial ischemia. Second, we examine whether measurement of the biomarkers in patients presenting to the Emergency Department with chest pain improves our ability to discriminate between non-ischemic chest pain versus unstable angina.
In Aim 3 b, we will test the hypothesis that the novel biomarkers will offer independent prognostic value beyond traditional clinical risk factors and established biomarkers in patients across several cardiac disease states including initial presentation with unstable angina and recent stabilization after ACS.
Given the mounting evidence in favor of early treatments for patients presenting with acute coronary syndromes, discovering sensitive and specific biomarkers that provide biochemical evidence of early myocardial injury could have a substantial positive impact on patient care. This project describes the application of a new metabolomics technology for biomarker discovery to address this clinical need.
|Rhee, Eugene P; Yang, Qiong; Yu, Bing et al. (2016) An exome array study of the plasma metabolome. Nat Commun 7:12360|
|Elmariah, Sammy; Farrell, Laurie A; Daher, Maureen et al. (2016) Metabolite Profiles Predict Acute Kidney Injury and Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement. J Am Heart Assoc 5:e002712|
|Lewis, Gregory D; Ngo, Debby; Hemnes, Anna R et al. (2016) Metabolic Profiling of Right Ventricular-Pulmonary Vascular Function Reveals Circulating Biomarkers of Pulmonary Hypertension. J Am Coll Cardiol 67:174-89|
|Cheng, Susan; Larson, Martin G; McCabe, Elizabeth L et al. (2015) Distinct metabolomic signatures are associated with longevity in humans. Nat Commun 6:6791|
|WÃ¼rtz, Peter; Havulinna, Aki S; Soininen, Pasi et al. (2015) Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation 131:774-85|
|Kalim, Sahir; Clish, Clary B; Deferio, Joseph J et al. (2015) Cross-sectional examination of metabolites and metabolic phenotypes in uremia. BMC Nephrol 16:98|
|Turer, Aslan T; Lewis, Gregory D; O'Sullivan, John F et al. (2014) Increases in myocardial workload induced by rapid atrial pacing trigger alterations in global metabolism. PLoS One 9:e99058|
|Roberts, Lee D; BostrÃ¶m, Pontus; O'Sullivan, John F et al. (2014) Î²-Aminoisobutyric acid induces browning of white fat and hepatic Î²-oxidation and is inversely correlated with cardiometabolic risk factors. Cell Metab 19:96-108|
|Magnusson, Martin; Lewis, Gregory D; Ericson, Ulrika et al. (2013) A diabetes-predictive amino acid score and future cardiovascular disease. Eur Heart J 34:1982-9|
|Roberts, Lee D; Gerszten, Robert E (2013) Toward new biomarkers of cardiometabolic diseases. Cell Metab 18:43-50|
Showing the most recent 10 out of 17 publications